{"id":"sm-13496","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, SM-13496 reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"SM-13496 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:18.301Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT05741502","phase":"PHASE4","title":"An Exploratory Analysis of Immune and Inflammatory Response Associated With Clozapine","status":"TERMINATED","sponsor":"Ohio State University","startDate":"2023-08-16","conditions":"Treatment-resistant Schizophrenia","enrollment":5},{"nctId":"NCT06433635","phase":"PHASE4","title":"Sequential Multiple Assignment Randomized Trial for Bipolar Depression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-10-01","conditions":"Bipolar I Disorder, Depression","enrollment":2726},{"nctId":"NCT07227103","phase":"PHASE2, PHASE3","title":"A Randomized, Double-Blind Controlled Comparison of NRX-101 vs. Placebo for Adults Being Treated With Transcranial Magnetic Stimulation for Treatment Resistant Depression","status":"NOT_YET_RECRUITING","sponsor":"NeuroRx, Inc.","startDate":"2026-03-01","conditions":"Treatment Resistant Depression","enrollment":120},{"nctId":"NCT06049953","phase":"","title":"Maternal And Infant Antipsychotic Study","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2023-09-29","conditions":"Antipsychotics, Pregnancy","enrollment":200},{"nctId":"NCT04002700","phase":"","title":"A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-05-06","conditions":"Stroke","enrollment":1234412},{"nctId":"NCT06328140","phase":"","title":"Sleep Quality, Cognitive Performance, and Computerized Cognitive Training","status":"WITHDRAWN","sponsor":"George West Mental Health Foundation d/b/a Skyland Trail","startDate":"2024-04-15","conditions":"Bipolar Disorder, Major Depressive Disorder, Psychosis","enrollment":""},{"nctId":"NCT02237417","phase":"PHASE4","title":"Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism","status":"COMPLETED","sponsor":"University of Utah","startDate":"2014-09-01","conditions":"Schizophrenia","enrollment":47},{"nctId":"NCT01569659","phase":"PHASE4","title":"High Dose Lurasidone for Patients With Treatment Resistant Schizophrenia","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2011-10","conditions":"Schizophrenia","enrollment":101},{"nctId":"NCT02731612","phase":"PHASE3","title":"Study of the Efficacy of Lurasidone in Cognitive Functioning in Bipolar Patients","status":"COMPLETED","sponsor":"Lakshmi N Yatham","startDate":"2017-05-08","conditions":"Bipolar Disorder","enrollment":100},{"nctId":"NCT06695676","phase":"","title":"Effects of Lurasidone on Left Ventricle Systolic Functions","status":"NOT_YET_RECRUITING","sponsor":"Aydin Adnan Menderes University","startDate":"2024-11","conditions":"Lurasidone Cardiotoxicity, Schizophrenia Patients, Bipolar Disorders","enrollment":62},{"nctId":"NCT03557931","phase":"PHASE2","title":"A Study to Assess the Safety and Efficacy of ASP4345 as Add-on Treatment for Cognitive Impairment in Subjects With Schizophrenia on Stable Doses of Antipsychotic Medication","status":"COMPLETED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-07-13","conditions":"Schizophrenia","enrollment":233},{"nctId":"NCT06527885","phase":"","title":"Lurasidone Non-Interventional Study in Schizophrenia Patients","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2022-10-21","conditions":"Schizophrenia","enrollment":61},{"nctId":"NCT03395392","phase":"PHASE2, PHASE3","title":"NRX-101 for Bipolar Depression With Subacute Suicidal Ideation","status":"COMPLETED","sponsor":"NeuroRx, Inc.","startDate":"2022-05-12","conditions":"Bipolar Depression, Suicidal Ideation and Behavior","enrollment":74},{"nctId":"NCT05213143","phase":"PHASE4","title":"The Safety and Efficacy of Lurasidone In Subjects With Schizophrenia Switched From Olanzapine","status":"TERMINATED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2021-12-30","conditions":"Schizophrenia","enrollment":13},{"nctId":"NCT05011669","phase":"PHASE4","title":"The Safety and Efficacy of Lurasidone With Different Initiation Dose in Chinese Acute Phase Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2021-08-16","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT04432688","phase":"","title":"The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2020-12-01","conditions":"Schizophrenia","enrollment":3192},{"nctId":"NCT02893371","phase":"","title":"Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies","status":"TERMINATED","sponsor":"University of New Mexico","startDate":"2016-09","conditions":"Bipolar Disorder","enrollment":1037352},{"nctId":"NCT03396068","phase":"PHASE3","title":"NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Suicidal Ideation","status":"UNKNOWN","sponsor":"NeuroRx, Inc.","startDate":"2019-12-01","conditions":"Bipolar Depression, Suicidal Ideation","enrollment":72},{"nctId":"NCT06128213","phase":"PHASE2","title":"NRX-101 for Complicated Urinary Tract Infection (UTI) Including Pyelonephritis","status":"UNKNOWN","sponsor":"NeuroRx, Inc.","startDate":"2024-03-31","conditions":"Urinary Tract Infections, Pyelonephritis","enrollment":13},{"nctId":"NCT03902613","phase":"PHASE4","title":"18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2019-02-07","conditions":"Bipolar Depression","enrollment":1},{"nctId":"NCT01431326","phase":"","title":"Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2011-11","conditions":"Adenovirus, Anesthesia, Anxiety","enrollment":3520},{"nctId":"NCT03786614","phase":"NA","title":"Antidepressant Discontinuation in Treatment Resistant Depression","status":"UNKNOWN","sponsor":"University of Louisville","startDate":"2019-06-20","conditions":"Treatment Resistant Depression","enrollment":30},{"nctId":"NCT04312503","phase":"","title":"Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia\"","status":"COMPLETED","sponsor":"Aziende Chimiche Riunite Angelini Francesco S.p.A","startDate":"2020-07-13","conditions":"Schizophrenia","enrollment":95},{"nctId":"NCT05779267","phase":"","title":"NRX-101 Expanded Access","status":"AVAILABLE","sponsor":"NeuroRx, Inc.","startDate":"","conditions":"Bipolar Depression, Bipolar Affective Disorder","enrollment":""},{"nctId":"NCT05351736","phase":"PHASE4","title":"Impact of Structural and Myelin Abnormalities on Cognitive Impairments in Recent-onset Schizophrenia - Before and After Lurasidone Treatment (MARYLU)","status":"UNKNOWN","sponsor":"Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","startDate":"2022-01-26","conditions":"Schizophrenia","enrollment":10},{"nctId":"NCT03465787","phase":"PHASE3","title":"A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia","status":"COMPLETED","sponsor":"Bukwang Pharmaceutical","startDate":"2018-04-09","conditions":"Schizophrenia","enrollment":210},{"nctId":"NCT04383691","phase":"PHASE3","title":"A Study of Lurasidone Compared With Placebo for the Treatment of Bipolar I Depression","status":"TERMINATED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2020-12-11","conditions":"Bipolar I Depression","enrollment":124},{"nctId":"NCT05480150","phase":"NA","title":"Chinese Longitudinal and Systematic Study of Bioplar Disorder","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-11-01","conditions":"Major Depressive Disorder, Bipolar Disorder, Mixed, Affective; Disorder, Organic","enrollment":10000},{"nctId":"NCT04742413","phase":"","title":"A 12-Month Observational Prospective Cohort Study to Analyze Cardiometabolic Profile Changes to Switch to Lurasidone in Patients With Schizophrenia. RESPECT Study.","status":"TERMINATED","sponsor":"Angelini Farmacéutica","startDate":"2020-12-29","conditions":"Schizophrenia","enrollment":9},{"nctId":"NCT03402152","phase":"PHASE2, PHASE3","title":"NRX101 Glx Biomarker Validation Study","status":"COMPLETED","sponsor":"NeuroRx, Inc.","startDate":"2018-11-01","conditions":"Bipolar Depression, Suicidal Ideation","enrollment":8},{"nctId":"NCT01614899","phase":"PHASE3","title":"A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2012-07-02","conditions":"Schizophrenia","enrollment":457},{"nctId":"NCT00711269","phase":"PHASE3","title":"Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2008-06-27","conditions":"Schizophrenia","enrollment":460},{"nctId":"NCT01614912","phase":"PHASE3","title":"Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2012-08","conditions":"Schizophrenia","enrollment":284},{"nctId":"NCT01986101","phase":"PHASE3","title":"A Phase III Study of SM-13496 in Patients With Bipolar I Depression.","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2014-02-19","conditions":"Bipolar Depression","enrollment":525},{"nctId":"NCT01986114","phase":"PHASE3","title":"A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.","status":"COMPLETED","sponsor":"Sumitomo Pharma Co., Ltd.","startDate":"2014-01-29","conditions":"Bipolar I Disorder","enrollment":495},{"nctId":"NCT01498770","phase":"","title":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-04-01","conditions":"Bipolar Disorder","enrollment":42},{"nctId":"NCT02213887","phase":"PHASE4","title":"Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2014-09","conditions":"Psychotic Disorders, Gastroesophageal Reflux","enrollment":""},{"nctId":"NCT02974010","phase":"PHASE2","title":"Sequential Therapy for the Treatment of Severe Bipolar Depression.","status":"COMPLETED","sponsor":"NeuroRx, Inc.","startDate":"2018-01-15","conditions":"Bipolar Depression, Suicidal Ideas, Suicidal Ideation","enrollment":22},{"nctId":"NCT03565068","phase":"PHASE1","title":"A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-20","conditions":"Schizophrenia","enrollment":75},{"nctId":"NCT03319953","phase":"PHASE2","title":"A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizophrenia","status":"COMPLETED","sponsor":"Neurocrine Biosciences","startDate":"2017-12-21","conditions":"Stable Schizophrenia","enrollment":23},{"nctId":"NCT02199743","phase":"PHASE4","title":"Lurasidone Effects on Tissue Glutamate in Schizophrenia","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2013-02","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":35},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":"Schizophrenia","enrollment":174},{"nctId":"NCT03627195","phase":"PHASE1","title":"A Study to Determine the Maximum Tolerated Dose of an Investigational Drug in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2018-06-07","conditions":"Schizophrenia","enrollment":40},{"nctId":"NCT03304457","phase":"PHASE4","title":"Lurasidone Vs Olanzapine on Neurotrophic Biomarkers and Cardiometabolic Parameters in Unmedicated Schizophrenia","status":"COMPLETED","sponsor":"All India Institute of Medical Sciences, Bhubaneswar","startDate":"2017-08-25","conditions":"Schizophrenia","enrollment":100},{"nctId":"NCT02181803","phase":"PHASE1","title":"MK-8189 Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-08-05","conditions":"Schizophrenia","enrollment":55},{"nctId":"NCT03393026","phase":"PHASE4","title":"A Study of Lurasidone HCl in Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Standard Chem. & Pharm. Co., Ltd.","startDate":"2018-01-03","conditions":"Schizophrenia","enrollment":54},{"nctId":"NCT01914393","phase":"PHASE3","title":"Pediatric Open-Label Extension Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2013-09-30","conditions":"Schizophrenia, Autism, Bipolar Depression","enrollment":702},{"nctId":"NCT02002832","phase":"PHASE3","title":"A Clinical Trial of Lurasidone in Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2013-12","conditions":"Schizophrenia","enrollment":388},{"nctId":"NCT01566162","phase":"PHASE3","title":"A Twelve Week, Open Label Extension Study in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2012-04","conditions":"Schizophrenia","enrollment":191},{"nctId":"NCT02174523","phase":"PHASE1","title":"Pharmacokinetic Study of Lurasidone After Multiple Oral Administration in Healthy Human Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2014-04","conditions":"Schizophrenia","enrollment":14},{"nctId":"NCT02174510","phase":"PHASE1","title":"A Pharmacokinetic Study of Lurasidone After Single Oral Administration in Healthy Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma (Suzhou) Co., Ltd.","startDate":"2014-03","conditions":"Schizophrenia","enrollment":37},{"nctId":"NCT01932541","phase":"PHASE4","title":"Open-Label Study of Latuda for the Treatment of Mania in Children and Adolescents 6-17 Years Old","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2017-01","conditions":"Mania, Bipolar I, Bipolar II","enrollment":""},{"nctId":"NCT02046369","phase":"PHASE3","title":"Lurasidone Pediatric Bipolar Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-03","conditions":"Bipolar I Depression","enrollment":350},{"nctId":"NCT02239094","phase":"NA","title":"Biosignatures of Latuda for Bipolar Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2015-01","conditions":"Bipolar Depression","enrollment":20},{"nctId":"NCT01731119","phase":"PHASE2","title":"Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and Adolescents","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2012-12","conditions":"Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder","enrollment":9},{"nctId":"NCT00806234","phase":"PHASE4","title":"Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2009-01","conditions":"Psychotic Disorders","enrollment":127},{"nctId":"NCT01911429","phase":"PHASE3","title":"Pediatric Schizophrenia Efficacy and Safety Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2013-08","conditions":"Schizophrenia","enrollment":327},{"nctId":"NCT01173874","phase":"PHASE3","title":"Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2010-07","conditions":"Schizophrenia","enrollment":120},{"nctId":"NCT02147379","phase":"PHASE3","title":"Lurasidone and Cognition in Bipolar I Disorder","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2014-05","conditions":"Bipolar I Disorder","enrollment":53},{"nctId":"NCT01485640","phase":"PHASE3","title":"Lurasidone Extended Use Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-06","conditions":"Schizophrenia, Bipolar Disorder","enrollment":162},{"nctId":"NCT01358357","phase":"PHASE3","title":"Bipolar Maintenance Study of Lurasidone Adjunctive to Lithium or Divalproex","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-06","conditions":"Bipolar I Disorder","enrollment":965},{"nctId":"NCT01575561","phase":"PHASE3","title":"This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2012-06","conditions":"Bipolar I Disorder","enrollment":377},{"nctId":"NCT01821378","phase":"PHASE3","title":"Lurasidone Low-Dose - High-Dose Study Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2013-05","conditions":"Schizophrenia","enrollment":412},{"nctId":"NCT01421134","phase":"PHASE3","title":"Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-09","conditions":"Major Depressive Disorder With Mixed Features","enrollment":211},{"nctId":"NCT01833897","phase":"PHASE4","title":"NMDA Antagonists in Bipolar Depression","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2013-03","conditions":"Bipolar Disorder","enrollment":8},{"nctId":"NCT01364818","phase":"","title":"Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2011-09","conditions":"Autism Spectrum Disorders, Psychosis, Fragile X Syndrome","enrollment":25},{"nctId":"NCT00868959","phase":"PHASE3","title":"Lurasidone - A 24-week Extension Study of Patients With Bipolar I Depression","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-04","conditions":"Bipolar Depression","enrollment":817},{"nctId":"NCT01620060","phase":"PHASE1","title":"Lurasidone Pediatric Pharmacokinetics Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2012-06","conditions":"Schizophrenia, Autism","enrollment":105},{"nctId":"NCT01423253","phase":"PHASE3","title":"Major Depressive Disorder With Mixed Features - Extension","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-09","conditions":"Major Depressive Disorder","enrollment":48},{"nctId":"NCT01435928","phase":"PHASE3","title":"PEARL Schizophrenia Maintenance","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2011-09","conditions":"Schizophrenia","enrollment":676},{"nctId":"NCT00088634","phase":"PHASE2","title":"A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2004-05","conditions":"Schizophrenia","enrollment":180},{"nctId":"NCT00790192","phase":"PHASE3","title":"Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-10","conditions":"Schizophrenia","enrollment":488},{"nctId":"NCT01911442","phase":"PHASE3","title":"Lurasidone Pediatric Autism Study","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2013-08","conditions":"Autism","enrollment":150},{"nctId":"NCT00641745","phase":"PHASE3","title":"Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-03","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":629},{"nctId":"NCT00789698","phase":"PHASE3","title":"Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-12","conditions":"Chronic Schizophrenia","enrollment":240},{"nctId":"NCT01143090","phase":"PHASE3","title":"A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-08","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":149},{"nctId":"NCT00615433","phase":"PHASE3","title":"Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-01","conditions":"Schizophrenia","enrollment":478},{"nctId":"NCT02282085","phase":"PHASE4","title":"Treatment Study Comparing Aripiprazole Once Monthly With Standard of Care Medication in Outpatients With Schizophrenia","status":"UNKNOWN","sponsor":"Matt Byerly","startDate":"2014-12","conditions":"Schizophrenia","enrollment":200},{"nctId":"NCT00549718","phase":"PHASE3","title":"Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2007-10","conditions":"Schizophrenia","enrollment":489},{"nctId":"NCT00044044","phase":"PHASE2","title":"A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-07","conditions":"Schizophrenia","enrollment":356},{"nctId":"NCT00868452","phase":"PHASE3","title":"Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-04","conditions":"Bipolar Depression","enrollment":348},{"nctId":"NCT00088621","phase":"PHASE2","title":"A Study to Test the Safety and Tolerability of a New Medication in the Treatment of Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2004-07","conditions":"Schizophrenia","enrollment":61},{"nctId":"NCT00044005","phase":"PHASE2","title":"Safety and Tolerability Study of Drug to Treat Schizophrenia","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2002-09","conditions":"Schizophrenia","enrollment":98},{"nctId":"NCT00868699","phase":"PHASE3","title":"Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-04","conditions":"Bipolar Depression","enrollment":505},{"nctId":"NCT01082146","phase":"PHASE1","title":"RI-AME Study OF [ISOTHIAZOLYL-3-14C]-LURASIDONE","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-08","conditions":"Pharmacokinetics, Metabolism","enrollment":6},{"nctId":"NCT01284517","phase":"PHASE3","title":"Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-11","conditions":"Bipolar Depression","enrollment":356},{"nctId":"NCT01979679","phase":"PHASE3","title":"A D2 Receptor Occupancy and fMRI Study in Schizophrenic Subjects Treated With Lurasidone","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2008-12","conditions":"Schizophrenia","enrollment":28},{"nctId":"NCT01143077","phase":"PHASE3","title":"A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2010-06","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":244},{"nctId":"NCT01423240","phase":"PHASE3","title":"Major Depressive Disorder With Mixed Features","status":"WITHDRAWN","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2012-01","conditions":"Major Depressive Disorder","enrollment":""},{"nctId":"NCT00549666","phase":"PHASE1","title":"A Randomized, Placebo-Controlled, Two-Period, Crossover Study to Evaluate the Effect of Lurasidone HCl on Oral Contraceptive Pharmacokinetics in Healthy Female Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2007-08","conditions":"Pharmacokinetics","enrollment":23},{"nctId":"NCT01074632","phase":"PHASE1","title":"Effect of Calories and Fat Content on the Pharmacokinetics of Lurasidone HCl","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-05","conditions":"Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder","enrollment":26},{"nctId":"NCT01074073","phase":"PHASE1","title":"Lithium Drug-Drug Interaction Study With Lurasidone HCl","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-08","conditions":"Schizophrenia","enrollment":24},{"nctId":"NCT01082263","phase":"PHASE1","title":"Midazolam Drug-Drug Interaction Study With Lurasidone HCl","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-10","conditions":"Schizophrenia Patients","enrollment":24},{"nctId":"NCT01082289","phase":"PHASE1","title":"Digoxin Drug-Drug Interaction With Lurasidone HCl","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-09","conditions":"Schizophrenia","enrollment":24},{"nctId":"NCT01082276","phase":"PHASE1","title":"Rifampin Drug-Drug Interaction Study With Lurasidone HCl","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-08","conditions":"Male, Healthy Normal Subjects","enrollment":20},{"nctId":"NCT01082250","phase":"PHASE1","title":"The Bioequivalence Of Two Different Lurasidone Formulations In Patients","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2008-07","conditions":"Schizophrenia","enrollment":52}],"_emaApprovals":[],"_faersSignals":[{"count":10,"reaction":"PSYCHOTIC DISORDER"},{"count":10,"reaction":"SCHIZOPHRENIA"},{"count":4,"reaction":"AGGRESSION"},{"count":4,"reaction":"DEPRESSION"},{"count":4,"reaction":"SUICIDE ATTEMPT"},{"count":3,"reaction":"MANIA"},{"count":2,"reaction":"ASTHMA"},{"count":2,"reaction":"OVERDOSE"},{"count":2,"reaction":"SEIZURE"},{"count":1,"reaction":"ACUTE PSYCHOSIS"}],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lurasidone HCl","Lurasidone"],"phase":"phase_3","status":"active","brandName":"SM-13496","genericName":"SM-13496","companyName":"Sumitomo Pharma Co., Ltd.","companyId":"sumitomo-pharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SM-13496 is a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}